Delaware | 26-1622110 | |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
Large accelerated filer | ¨ | Accelerated filer | x | |||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | ¨ |
Title of Securities to be Registered | Amount to be Registered(1) | Proposed Maximum Offering Price Per Share | Proposed Maximum Aggregate Offering Price | Amount of Registration Fee | ||||
Common Stock, par value $0.0001 per share | 407,819 shares(2) | $9.30 (3) | $3,792,716.70 | $473 | ||||
Common Stock, par value $0.0001 per share | 1,631,279 shares(4) | $9.30 (3) | $15,170,894.70 | $1,889 |
(1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued under the Selecta Biosciences, Inc. 2016 Employee Stock Purchase Plan (“ESPP”) and the Selecta Biosciences, Inc. 2016 Incentive Award Plan (the “Incentive Plan”) to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) | Consists of 407,819 shares of Common Stock that may become issuable under the ESPP pursuant to its terms. |
(3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Market on March 28, 2018. |
(4) | Consists of 1,631,279 shares of Common Stock that may become issuable under the Incentive Plan pursuant to its terms. |
Item 8. Exhibits. | ||
Number | Description | |
4.1 | ||
4.2 | ||
5.1+ | ||
23.1+ | ||
23.2 + | ||
24.1+ | Power of attorney (included on signature pages below) | |
99.1 | ||
99.2 |
SELECTA BIOSCIENCES, INC. | ||
By: | /s/ Werner Cautreels, Ph.D. | |
Werner Cautreels, Ph.D. | ||
President, Chief Executive Officer and Director |
Signature | Title | Date | |
/s/ Werner Cautreels, Ph.D. | President, Chief Executive Officer and Director | April 3, 2018 | |
Werner Cautreels, Ph.D. | (Principal Executive Officer) | ||
/s/ John Leaman, M.D. | Chief Financial Officer, Head of Corporate Strategy, and Treasurer | April 3, 2018 | |
John Leaman, M.D. | (Principal Financial and Accounting Officer) | ||
/s/ Timothy C. Barabe | Director | April 3, 2018 | |
Timothy C. Barabe | |||
/s/ Omid Farokhzad, M.D. | Director | April 3, 2018 | |
Omid Farokhzad, M.D. | |||
/s/ Peter Barton Hutt | Director | April 3, 2018 | |
Peter Barton Hutt | |||
/s/ Amir Nashat, Ph.D | Director | April 3, 2018 | |
Amir Nashat, Ph.D | |||
/s/ Aymeric Sallin | Director | April 3, 2018 | |
Aymeric Sallin | |||
/s/ Timothy Springer, Ph.D. | Director | April 3, 2018 | |
Timothy Springer, Ph.D. | |||
/s/ Patrick Zenner | Director | April 3, 2018 | |
Patrick Zenner |
Exhibit 5.1 | ||||
200 Clarendon Street | ||||
Boston, Massachusetts 02116 | ||||
Tel: +1.617.948.6000 Fax: +1.617.948.6001 | ||||
www.lw.com | ||||
FIRM / AFFILIATE OFFICES | ||||
Beijing | Moscow | |||
Boston | Munich | |||
Brussels | New York | |||
Century City | Orange County | |||
Chicago | Paris | |||
Dubai | Riyadh | |||
Dusseldorf | Rome | |||
Franfurt | San Diego | |||
Hamburg | San Francisco | |||
Hong Kong | Seoul | |||
Houston | Shanghai | |||
April 3, 2018 | London | Silicon Valley | ||
Los Angeles | Singapore | |||
Madrid | Tokyo | |||
Selecta Biosciences, Inc. | Milan | Washington, D.C. | ||
480 Arsenal Way | ||||
Watertown, MA 02139 | File No. 049821-0014 |
,8K31?#Z/*T[+),S*0(P.Q^G>MWP#IMI!X0@D2-&>Z!
M:9B,[N2,'VK)UKPM>>';\ZYX3R O,UJ.01WP.X]J .HNM6LO#D6FV-T9/WVV
M"-@N1D #)/:MBO,->\36_BNQTBWM8V2^-XN^(]4[9!].:]/ PH% !7B/CVP^
MP>,+L*,)-B9?Q'/ZYKVZO-OBQ8\V%^HZ[H6/ZC^M &M\,;[[3X8:V8Y:VF('
MT/(_K5/XK7_EZ;9V*MS-(9&'LHX_4_I61\*[_P G6KJS8\3Q;E'NI_P)K/\
MB-?_ &WQ=+&IREL@B'UZG]30!M?"K3Q(VH7DBY7:(5S[\G^E3*RCZ9X_2O7_ %A]A\'VVX8>